# Abbott Labs CDR (CAD Hedged) (ABT.TO) fundamentals

Data as of 2026-11-04. TSX, Canada. Sector: Healthcare / Medical Devices & Supplies. Price C$19.09, market value C$253.9 billion.

## Valuation
- **P/E (trailing): 41.5×** (5-yr avg 45.4×, 3-yr avg 45.4×). Abbott Labs CDR (CAD Hedged) trades at 41.5× trailing earnings, close to its own five-year average of 45.4×. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 5.6×**. Each dollar of revenue is priced at 5.6×.
- **Price / book: 1.8×**. The shares trade at 1.8× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 21.9×**. Enterprise value is 21.9× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.9%** (5-yr avg 2.5%). Free cash flow equals 2.9% of the market value, in line with its five-year average of 2.5%.
- **Earnings yield: 2.4%**. The inverse of the P/E: 2.4% of the price is earned each year.

## Profitability
- **Gross margin: 56.3%**. Abbott Labs CDR (CAD Hedged) keeps 56.3% of revenue after the direct cost of what it sells.
- **Operating margin: 17.1%**. 17.1% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 14.7%**. 14.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.5%**. 12.5% on shareholders' equity is solid.
- **Return on invested capital: 10.4%**. Return on all capital, debt included, is 10.4%.
- **Return on assets: 7.2%**. Each dollar of assets produces 7.2% of profit.

## Growth
- **Revenue growth (1 yr): 5.7%** (3-yr 0.5%/yr). Revenue grew 5.7% over the last year.
- **EPS growth (1 yr): -51.3%** (3-yr -1.6%/yr). Earnings per share fell 51.3%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -1.8%/yr**. Free cash flow has compounded at -1.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.27**. Debt is 0.27 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.4×**. It would take 0.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 14.4×**. Operating profit covers interest 14.4× over, a safe margin.
- **Current ratio: 1.58** (quick 1.18). Current assets cover the next year's liabilities 1.58 times.
- **Altman Z-score: 6.15**. A Z-score of 6.15 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Abbott Labs CDR (CAD Hedged) does not currently pay a dividend, but it returned 0.3% of its market value through buybacks over the last year.

## Price and momentum
- **From 52-week high: -16.2%** (32.0% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 0.16** (volatility 30%). Beta of 0.16 against the S&P/TSX Composite: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ABT.TO · Page: https://foliofundamentals.com/stocks/abt.to

Not investment advice.